Idursulfase in Hunter syndrome treatment

Drugs of Today

Volumn 43, Issue 11, 2007, Pages 759-767

  Zareba, Grazyna ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; IDURONATE 2 SULFATASE; PLACEBO;

ADENOID; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY; ARTHRALGIA; BEHAVIOR THERAPY; BONE DISEASE; BONE DYSPLASIA; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; COMMUNICATING HYDROCEPHALUS; CYANOSIS; DEVELOPMENTAL DISORDER; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EAR INFECTION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FACE MALFORMATION; FEVER; HAIR GROWTH; HEADACHE; HEARING LOSS; HEART ARRHYTHMIA; HUMAN; HUNTER SYNDROME; HYPERTENSION; HYPOTENSION; HYPOXIA; INFECTION; INGUINAL HERNIA; IRRITABILITY; JOINT LIMITATION; JOINT STIFFNESS; LUNG EMBOLISM; LUNG FUNCTION; LYSOSOME STORAGE DISEASE; MENTAL DEFICIENCY; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; NOSE DISEASE; ORGAN SIZE; PNEUMONIA; PRURITUS; RESPIRATORY ARREST; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SHORT STATURE; SIDE EFFECT; SKIN DISEASE; SLEEP APNEA SYNDROME; SPEECH THERAPY; STEM CELL TRANSPLANTATION; TONSIL DISEASE; TONSIL ENLARGEMENT; TOOTH DISEASE; UMBILICAL HERNIA; URTICARIA; VALVULAR HEART DISEASE; VISUAL IMPAIRMENT; WALKING;

ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; GLYCOPROTEINS; HUMANS; IDURONATE SULFATASE; MALE; MUCOPOLYSACCHARIDOSIS II;

EID: 38349068921     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.11.1157619     Document Type: Review

References (39)

1. Neufeld, E.F., Muenzer, J. The mucopolysaccharidoses. In: Scriver, C.R. (Ed.). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, 2001, 3421-52.
2. Fenton, C. and Rogers, W., Mucopolysaccharidosis Type II. Available at http://www. emedicine.com
3. Vellodi, A., Young, E., Cooper, A., Lidchi, V., Winchester, B., Wraith, J.E. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999, 22(5): 638-48.
4. Coppa, G.V., Gabrielli, O., Zampini, L., Jetzequel, A.M., Miniero, R., Busca, A., De Luca, T., Di Natale, P. Bone marrow transplantation in Hunter syndrome. J Inherit Metab Dis 1995, 18(1): 91-2.
5. Mullen, C.A., Thompson, J.N., Richard, L.A., Chan, K.W. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant 2000, 25(10): 1093-7.
6. Anonymous. Idursulfase: I2S, iduronato-2-sulfatase. Drugs R D 2006, 7: 254-8.
7. FDA. First treatment for Hunter syndrome. FDA Consum 2006, 40: 5.
8. FDA. Treatment for Hunter syndrome approved. FDA Consum 2006, 40: 4.
9. FDA. Elaprase.Medical reviews. Application 125151/0. Available at http://www.fda.gov
10. Gutierrez-Solana, L.G. Clinical study of enzyme replacement therapy with idursulfase. Rev Neurol. 2007, 44 Suppl 1: S7-S11.
11. Meikle, P.J., Hopwood, J.J., Clague, A.E., Carey, W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281(3): 249-54.
12. Young, I.D., Harper, P.S. Incidence of Hunter's syndrome. Hum Genet 1982, 60(4): 391-2.
13. Balaghova, J., Schwartz, R.A., Baranova, Z., Halagovec, A. Mucopolysaccharidoses Types I-VII. Available at http://www.emedicine.com
14. Tuschl, K., Gal, A., Paschke, E., Kircher, S., Bodamer, O.A. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005, 32(4): 270-2.
15. Muenzer, J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004, 144: S27-34.
16. Ochiai, T., Ito, K., Okada, T., Chin, M., Shichino, H., Mugishima, H. Significance of extensive Mongolian spots in Hunter's syndrome. Br J Dermatol 2003, 148(6): 1173-8.
17. Norman-Taylor, F., Fixsen, J.A., Sharrard, W.J. Hunter's syndrome as a cause of childhood carpal tunnel syndrome: a report of three cases. J Pediatr Orthop B 1995, 4(1): 106-9.
18. Ito, K., Ochiai, T., Suzuki, H. et al. The effect of haematopoietic stem cell transplant on papules with 'pebbly' appearance in Hunter's syndrome. Br J Dermatol 2004, 151(1): 207-11.
19. Ochiai, T., Ito, K., Shichino, H., Chin, M., Mugishima, H. Ultrastructural findings of cutaneous nerves in patients with Hunter's syndrome following hematopoietic stem cell transplant. Med Mol Morphol 2005, 38(2): 118-22.
20. Kakkis, E.D., Schuchman, E., He, X., Wan, Q., Kania, S., Wiemelt, S., Hasson, C.W., O'Malley, T., Weil, M.A., Aguirre, G.A., Brown, D.E., Haskins, M.E. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001, 344(3): 182-8.
21. Wraith, J.E., Clarke, L.A., Beck, M. et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004, 144(5): 581-8.
22. Harmatz, P., Giugliani, R., Schwartz, I. et al. MPS VI Phase 3 Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on, open-label extension study. J Pediatr 2006, 148(4): 533-9.
23. Eng, C.M., Guffon, N., Wilcox, W.R. et al. International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human [alpha]-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001, 345(1): 9-16.
24. Schiffmann, R., Kopp, J.B., Austin, H.A. 3rd et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285(21): 2743-9.
25. Wilcox, W.R., Banikazemi, M., Guffon, N., Waldek, S., Lee, P., Linthorst, G.E., Desnick, R.J., Germain, D.P. International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75(1): 65-74.
26. Rosenberg, M., Kingma, W., Fitzpatrick, M.A., Richards, S.M. Immunosurveillance of-alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999, 93(6): 2081-8.
27. MICROMEDEX® Healthcare Series. Idursulfase.
28. Product Information. ELAPRASE™ IV injection, idursulfase IV injection. Shire Human Genetic Therapies, Inc, Cambridge, MA, 2006.
29. Muenzer, J., Wraith, J.E., Beck, M. et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006, 8(8): 465-73.
30. Gort, L., Chabas, A., Coll, M.J. Hunter disease in the Spanish population: molecular analysis in 31 families. J Inherit Metab Dis 1998, 21(6): 655-61.
31. Lissens, W., Seneca, S., Liebaers, I. Molecular analysis in 23 Hunter disease families. J Inherit Metab Dis 1997, 20(3): 453-6.
32. Timms, K.M., Bondeson, M.L., Ansari-Lari, M.A., Lagerstedt, K., et al. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet 1997, 6(3): 479-86.
33. Vafiadaki, E., Cooper, A., Heptinstall, L.E., Hatton, C.E., Thornley, M., Wraith, J.E. Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child 1998, 79(3): 237-41.
34. Li, P., Bellows, A.B., Thompson, J.N. Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J Med Genet 1999, 36(1): 21-7.
35. Hopwood, J.J., Bunge, S., Morris, C.P., Wilson, P.J., Steglich, C., Beck, M., Schwinger, E., Gal, A. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mutat 1993, 2(6): 435-42.
36. Garcia, A.R., Dacosta, J.M., Pan, J., Muenzer, J., Lamsa, J.C. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. Mol Genet Metab 2007, 91(2): 183-90.
37. Muenzer, J., Lamsa, J.C., Garcia, A., Dacosta, J., Garcia, J., Treco, D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002, 91(439): 98-9.
38. Muenzer, J., Gucsavas-Calikoglu, M., McCandless, S.E., Schuetz, T.J., Kimura, A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007, 90(3): 329-37.
39. Hong, Y., Yu, S.S., Kim, J.M., Lee, K., Na, Y.S., Whitley, C.B., Sugimoto, Y., Kim. S. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome. J Gene Med 2003, 5(1): 18-29.